Immune-based therapies for prostate cancer

Direct Gene Transfer into Mouse Muscle in Vivo

1990 • 3,985 citations

Genetic immunization is a simple method for eliciting an immune response

1992 • 1,505 citations

Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified.

1996 • 1,129 citations

The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.

1993 • 986 citations

Gene inoculation generates immune responses against human immunodeficiency virus type 1.

1993 • 655 citations

Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma

2000 • 630 citations

Immunotherapy of Hormone-Refractory Prostate Cancer With Antigen-Loaded Dendritic Cells

2000 • 627 citations

Human granulocyte-macrophage colony-stimulating factor is a neutrophil activator

1985 • 566 citations

Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses.

1994 • 550 citations

γδ T cells for immune therapy of patients with lymphoid malignancies

2003 • 525 citations

Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.

1999 • 468 citations

In vivo generation of human dendritic cell subsets by Flt3 ligand

2000 • 397 citations

Dendritic Cells Injected Via Different Routes Induce Immunity in Cancer Patients

2001 • 346 citations

Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines

1996 • 308 citations

A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.

2000 • 300 citations

Hematologic effects of flt3 ligand in vivo in mice

1996 • 272 citations

Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro.

1990 • 269 citations

In Vitro Generation of Human Cytotoxic T Lymphocytes Specific for Peptides Derived From Prostate-Specific Antigen

1997 • 267 citations

Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer.

2000 • 260 citations

Dendritic Cell-Based Xenoantigen Vaccination for Prostate Cancer Immunotherapy

2001 • 257 citations

Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma

1994 • 257 citations

Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines

1996 • 256 citations

Molecular Characterization of Defective Antigen Processing in Human Prostate Cancer

1995 • 240 citations

Induction of γδ T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo

2003 • 239 citations

Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy.

1995 • 237 citations

Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV‐PSA) in patients with metastatic androgen‐independent prostate cancer

2002 • 230 citations

Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer

1999 • 206 citations

FLT3 Ligand Induces the Generation of Functionally Active Dendritic Cells in Mice

1997 • 193 citations

Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers.

1998 • 184 citations

Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines.

1994 • 181 citations

Vγ2Vδ2 T-cell receptor–mediated recognition of aminobisphosphonates

2001 • 173 citations

Cytotoxic T-cell responses in mice infected with influenza and vaccinia viruses vary in magnitude with H-2 genotype.

1978 • 166 citations

Autoimmune prostatitis: Evidence of T cell reactivity with normal prostatic proteins

1997 • 147 citations

Targeting of Tumor Cells for Human γδ T Cells by Nonpeptide Antigens

2001 • 146 citations

Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer

2000 • 127 citations

Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity

1996 • 120 citations

Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model.

1997 • 117 citations

Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide

1998 • 114 citations

A recombinant vaccinia virus expressing human prostate‐specific antigen (PSA): Safety and immunogenicity in a non‐human primate

1995 • 109 citations

Recognition of hepatitis B surface antigen by human T lymphocytes. Proliferative and cytotoxic responses to a major antigenic determinant defined by synthetic peptides.

1988 • 107 citations

Induction of cellular and humoral immune responses to tumor cells and peptides in HLA‐A24 positive hormone‐refractory prostate cancer patients by peptide vaccination

2003 • 105 citations

FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma.

1998 • 103 citations

Cytokine regulation of eosinophil function

1992 • 101 citations

Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen

1997 • 99 citations

Prostate-Specific Antigen Kinetics as a Measure of the Biologic Effect of Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Serologic Progression of Prostate Cancer

2002 • 97 citations

Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen.

2002 • 96 citations

The Nude Mouse vs. The Hypothesis of Immunological Surveillance

1976 • 91 citations

Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu–overexpressing cancers

2002 • 87 citations

Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine

1998 • 85 citations

Immunologic approaches to the treatment of prostate cancer.

1999 • 83 citations

ANTIBODY IMMUNITY TO PROSTATE CANCER ASSOCIATED ANTIGENS CAN BE DETECTED IN THE SERUM OF PATIENTS WITH PROSTATE CANCER

2000 • 76 citations

Recognition of prostate-specific antigenic peptide determinants by human CD4 and CD8 T cells

1998 • 74 citations

Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8⁺ T cells in prostate cancer patients

2002 • 72 citations

GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial

1999 • 69 citations

Ganglioside vaccines with emphasis on GM2.

1998 • 66 citations

Engineering enhancement of immune responses to DNA-based vaccines in a prostate cancer model in rhesus macaques through the use of cytokine gene adjuvants.

2001 • 60 citations

Naturally occurring prostate cancer antigen‐specific T cell responses of a Th1 Phenotype can be detected in patients with prostate cancer

2001 • 57 citations

Identification of Antigen-Specific IgG in Sera from Patients with Chronic Prostatitis

2004 • 55 citations

Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant.

2003 • 49 citations

Occult Carcinoma of the Prostate: an Oversight of Immune Surveillance—A Working Hypothesis

1974 • 48 citations

The effect of granulocyte—macrophage colony‐stimulating factor (GM‐CSF) on hepatitis B vaccination in haemodialysis patients

1996 • 48 citations

DNA vaccines: an active immunization strategy for prostate cancer

2003 • 47 citations

Identification of T helper epitopes from prostatic acid phosphatase.

2001 • 46 citations

An immunohistochemical characterisation of the inflammatory cell infiltrate in benign and malignant prostatic disease

1990 • 45 citations

Phase II Trial of GM-CSF in Advanced Prostate Cancer

2001 • 43 citations

Epitope selection and development of peptide based vaccines to treat cancer

1995 • 41 citations

Flt3-ligand induces transient tumor regression in an ectopic treatment model of major histocompatibility complex-negative prostate cancer.

2000 • 38 citations

Identification of Naturally Processed CD4 T Cell Epitopes from the Prostate-Specific Antigen Kallikrein 4 Using Peptide-Based In Vitro Stimulation

2002 • 37 citations

Innate T-Cell Immunity in HIV Infections: The Role of Vg9Vd2 T Lymphocytes

2002 • 36 citations

The lymphatics of the prostate.

1966 • 34 citations

Identification of MHC class II-restricted T-cell epitopes in prostate-specific membrane antigen.

2003 • 34 citations

In vivo γδ T Cell Priming to Mycobacterial Antigens by Primary Mycobacterium tuberculosis Infection and Exposure to Nonpeptidic Ligands

1999 • 34 citations

Safety and Biological Activity of Repeated Doses of Recombinant Human Flt3 Ligand in Patients with Bone Scan-Negative Hormone-Refractory Prostate Cancer

2004 • 33 citations

Evidence of determinant spreading in the antibody responses to prostate cell surface antigens in patients immunized with prostate-specific antigen.

2002 • 29 citations

VACCINES AS TREATMENT STRATEGIES FOR RELAPSED PROSTATE CANCER

2001 • 20 citations

Natural T Cell Immunity to Intracellular Pathogens and Nonpeptidic Immunoregulatory Drugs

2001 • 15 citations

Defective cell-mediated immunity in carcinoma of the prostate.

1976 • 13 citations

A randomized pilot study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen independent prostate cancer

2006 • 12 citations

1159. A Phase I/II Study of High Dose Allogeneic GM-CSF Gene-Transduced Prostate Cancer Cell Line Vaccine in Patients with Metastatic Hormone-Refractory Prostate Cancer

2003 • 6 citations

The immune response to prostate cancer: An evaluation and a review

1980 • 4 citations

DNA vaccine encoding a prostate-specific protein elicits CD8 T cell immunity and tissue-specific inflammation

2004 • 2 citations